The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| Clovis Oncology, Inc. | Common Stock | 189464100 | 35,803,718 | 407,416 | SH | OTR | 0 | 407,416 | 0 | ||
| Five Prime Therapeutics, Inc. | Common Stock | 33830X104 | 27,129,055 | 1,092,152 | SH | OTR | 0 | 1,092,152 | 0 | ||
| CymaBay Therapeutics, Inc. | Common Stock | 23257D103 | 2,820,736 | 1,048,601 | SH | OTR | 0 | 1,048,601 | 0 | ||
| Achaogen, Inc. | Common Stock | 004449104 | 7,725,346 | 1,281,152 | SH | OTR | 0 | 1,281,152 | 0 | ||
| Biotie Therapies Corp. | ADS | 09074D103 | 5,365,379 | 268,672 | SH | OTR | 0 | 268,672 | 0 | ||